PROF Earnings

PROF reported its FY2025Q4 earnings on 2026-03-05, showcasing a revenue of against an estimate of 7.65M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.27 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following PROF's FY2025Q4 earnings announcement on 2026-03-05, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, PROF's stock price tends to shift by an average of 2.01% in the 10 days leading up to earnings and -5.83% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate PROF's annual revenue to reach 7.84M, while the EPS is projected at -0.38. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between PROF's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, PROF's stock price typically moves by 2.01% in the 10 days before its earnings and -5.83% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.38 and revenue of 7.84M.

The earnings call reveals strong financial performance with an 87% revenue increase and improved gross margins. Positive guidance with 70%-75% growth expectations, supported by a robust pipeline, indicates optimism. The Q&A highlights significant commercial payer rates and Medicare reimbursement progress, enhancing profitability potential. While there are competitive and operational risks, the company's strategic focus on reimbursement and market access, along with promising clinical outcomes, supports a positive outlook. Despite some management vagueness, the overall sentiment is positive, likely resulting in a 2%-8% stock price increase.